Published in Inflamm Bowel Dis on December 01, 2017
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet (2007) 13.74
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Guidelines for the management of inflammatory bowel disease in adults. Gut (2011) 5.42
Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol (2012) 4.78
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Functional Dyspepsia. N Engl J Med (2015) 3.66
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet (2005) 2.93
Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2012) 2.46
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 2.19
Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol (2013) 2.18
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Initial management of dyspepsia in primary care: an evidence-based approach. Br J Gen Pract (2013) 1.90
Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet (2005) 1.81
Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature (2013) 1.79
Mechanisms of plant defense against insect herbivores. Plant Signal Behav (2012) 1.74
TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology (2006) 1.73
Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. Inflamm Bowel Dis (2007) 1.47
Direction of the brain--gut pathway in functional gastrointestinal disorders. Gut (2012) 1.43
Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. Gut (2010) 1.41
Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci U S A (2004) 1.38
Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol (2012) 1.32
Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nat Genet (2011) 1.30
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology (2002) 1.21
Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis (2007) 1.18
Losses to follow-up limit conclusions regarding the efficacy of branched-chain amino acids in patients with hepatic encephalopathy. Am J Gastroenterol (2011) 1.09
Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail (2013) 1.07
Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol (2012) 1.06
Further evidence of IBD5/CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitis. Am J Hum Genet (2003) 1.05
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis (2013) 1.04
The double loop mattress suture. Wound Repair Regen (2014) 1.03
HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol (2002) 1.02
Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. Invest Ophthalmol Vis Sci (2007) 1.00
The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: differing perceptions from a survey of adult and paediatric gastroenterologists. J Crohns Colitis (2012) 0.98
Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol (2012) 0.96
Pneumococcal infection in patients with coeliac disease. Eur J Gastroenterol Hepatol (2008) 0.93
Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J (2013) 0.92
Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflamm Bowel Dis (2008) 0.91
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol (2015) 0.89
Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis (2015) 0.89
Diagnosis and treatment of irritable bowel syndrome. Discov Med (2011) 0.88
Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet (2010) 0.87
Providing patients with global cardiovascular risk information: is knowledge power? Arch Intern Med (2010) 0.86
The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol (2004) 0.85
Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis (2011) 0.85
Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis (2004) 0.85
Contribution of histological, serological, and genetic factors to the clinical heterogeneity of adult-onset coeliac disease. Scand J Gastroenterol (2009) 0.83
Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. Gastroenterol Clin North Am (2011) 0.82
The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics (2005) 0.82
Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med (2009) 0.82
Galectin-3 in heart failure: more answers or more questions? J Am Heart Assoc (2012) 0.81
Can we prevent heart failure with exercise? J Am Coll Cardiol (2012) 0.81
Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol (2011) 0.80
Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad (2009) 0.79
Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J Gastroenterol (2013) 0.79
The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum (2004) 0.79
Opportunistic infections and vaccinations in IBD patients. J Crohns Colitis (2011) 0.79
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis (2011) 0.78
Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis. World J Gastroenterol (2009) 0.78
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2009) 0.78
Efficacy of traditional chinese medicine in functional constipation. Am J Gastroenterol (2011) 0.78
Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? J Am Coll Cardiol (2012) 0.77
Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis (2015) 0.77
Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.77
"Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 0.76
Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Ther Adv Chronic Dis (2013) 0.76
Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.76
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. J Crohns Colitis (2011) 0.75
Clopidogrel with or without omeprazole in coronary disease. N Engl J Med (2011) 0.75
Overlap among the functional gastrointestinal disorders. Am J Gastroenterol (2010) 0.75
Bran and irritable bowels. Bran's deleterious effects: much ado about nothing. BMJ (2009) 0.75
Reply to Machicado JD, Villafuerte-Galvez J, Marcos LA, Prevalence of irritable bowel syndrome in South America. Clin Gastroenterol Hepatol (2012) 0.75
Disease activity and venous thromboembolism in inflammatory bowel disease. Lancet (2010) 0.75
VSL#3 and remission in active ulcerative colitis: larger studies required. Am J Gastroenterol (2011) 0.75
Breath testing and antibiotics for possible bacterial overgrowth in irritable bowel syndrome. Expert Rev Anti Infect Ther (2010) 0.75
The American College of Gastroenterology irritable bowel syndrome monograph: translating systematic review data to clinical practice. Gastroenterology (2009) 0.75
Helicobacter pylori eradication. Lancet (2011) 0.75
Is the benefit of granulocyte monocyte adsorptive apheresis in ulcerative colitis overstated? Dig Dis Sci (2010) 0.75
Treatment of Helicobacter pylori in Latin America. Lancet (2012) 0.75
Treatment of chronic gastro-oesophageal reflux disease. BMJ (2009) 0.75
Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome. Am J Gastroenterol (2011) 0.75